Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies


Por: Broce, I, Karch, CM, Wen, N, Fan, CC, Wang, YP, Tan, CH, Kouri, N, Ross, OA, Hoglinger, GU, Muller, U, Hardy, J, Momeni, P, Hess, CP, Dillon, WP, Miller, ZA, Bonham, LW, Rabinovici, GD, Rosen, HJ, Schellenberg, GD, Franke, A, Karlsen, TH, Veldink, JH, Ferrari, R, Yokoyama, JS, Miller, BL, Andreassen, OA, Dale, AM, Desikan, RS, Sugrue, LP, Clarimón J., Lleó A., Blesa R., Hardy, John

Publicada: 1 ene 2018
Resumen:
Background Converging evidence suggests that immune-mediated dysfunction plays an important role in the pathogenesis of frontotemporal dementia (FTD). Although genetic studies have shown that immune-associated loci are associated with increased FTD risk, a systematic investigation of genetic overlap between immune-mediated diseases and the spectrum of FTD-related disorders has not been performed. Methods and findings Using large genome-wide association studies (GWASs) (total n = 192,886 cases and controls) and recently developed tools to quantify genetic overlap/pleiotropy, we systematically identified single nucleotide polymorphisms (SNPs) jointly associated with FTD-related disorders-namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS)-and 1 or more immune-mediated diseases including Crohn disease, ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), and psoriasis. We found up to 270-fold genetic enrichment between FTD and RA, up to 160-fold genetic enrichment between FTD and UC, up to 180-fold genetic enrichment between FTD and T1D, and up to 175-fold genetic enrichment between FTD and CeD. In contrast, for CBD and PSP, only 1 of the 6 immune-mediated diseases produced genetic enrichment comparable to that seen for FTD, with up to 150-fold genetic enrichment between CBD and CeD and up to 180-fold enrichment between PSP and RA. Further, we found minimal enrichment between ALS and the immune-mediated diseases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold). For FTD, at a conjunction false discovery rate < 0.05 and after excluding SNPs in linkage disequilibrium, we found that 8 of the 15 identified loci mapped to the human leukocyte antigen (HLA) region on Chromosome (Chr) 6. We also found novel candidate FTD susceptibility loci within LRRK2 (leucine rich repeat kinase 2), TBKBP1 (TBK1 binding protein 1), and PGBD5 (piggyBac transposable element derived 5). Functionally, we found that the expression of FTD +/- immune pleiotropic genes (particularly within the HLA region) is altered in postmortem brain tissue from patients with FTD and is enriched in microglia/macrophages compared to other central nervous system cell types. The main study limitation is that the results represent only clinically diagnosed individuals. Also, given the complex interconnectedness of the HLA region, we were not able to define the specific gene or genes on Chr 6 responsible for our pleiotropic signal. Conclusions We show immune-mediated genetic enrichment specifically in FTD, particularly within the HLA region. Our genetic results suggest that for a subset of patients, immune dysfunction may contribute to FTD risk. These findings have potential implications for clinical trials targeting immune dysfunction in patients with FTD.

Filiaciones:
Broce, I:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

Karch, CM:
 Washington Univ, Dept Psychiat, St Louis, MO USA

Wen, N:
 Washington Univ, Dept Psychiat, St Louis, MO USA

Fan, CC:
 Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA

Wang, YP:
 Univ Oslo, Inst Clin Med, Norwegian Ctr Mental Disorders Res NORMENT, Oslo, Norway

 Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway

Tan, CH:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

Kouri, N:
 Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA

Ross, OA:
 Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA

Hoglinger, GU:
 Tech Univ Munich, Dept Neurol, Munich, Germany

 German Ctr Neurodegenerat Dis DZNE, Munich, Germany

 Munich Cluster Syst Neurol SyNergy, Munich, Germany

Muller, U:
 Justus Liebig Univ, Inst Humangenet, Giessen, Germany

Hardy, J:
 UCL, Inst Neurol, Dept Mol Neurosci, London, England

Momeni, P:
 Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lab Neurogenet, Lubbock, TX 79430 USA

Hess, CP:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

Dillon, WP:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

Miller, ZA:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Bonham, LW:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Rabinovici, GD:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Rosen, HJ:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Schellenberg, GD:
 Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA

Franke, A:
 Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany

Karlsen, TH:
 Oslo Univ Hosp, Rikshosp, Norwegian PSC Res Ctr, Res Inst Internal Med,Div Canc Med Surg & Transpl, Oslo, Norway

 Univ Bergen, Inst Med, Div Gastroenterol, Bergen, Norway

 Oslo Univ Hosp, Rikshosp, KG Jebsen Inflammat Res Ctr, Res Inst Internal Med,Div Canc Med Surg & Transpl, Oslo, Norway

Veldink, JH:
 Univ Med Ctr Utrecht, Dept Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands

Ferrari, R:
 UCL, Inst Neurol, Dept Mol Neurosci, London, England

Yokoyama, JS:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Miller, BL:
 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Andreassen, OA:
 Univ Oslo, Inst Clin Med, Norwegian Ctr Mental Disorders Res NORMENT, Oslo, Norway

 Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway

Dale, AM:
 Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA

 Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA

 Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

Desikan, RS:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

Sugrue, LP:
 Univ Calif San Francisco, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

Clarimón J.:
 Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

 Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain

Lleó A.:
 Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

 Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain

Blesa R.:
 Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

 Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain

Hardy, John:
 UCL, Inst Neurol, Dept Mol Neurosci, London, England
ISSN: 15491277





PLOS MEDICINE
Editorial
PUBLIC LIBRARY SCIENCE, 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 15 Número: 1
Páginas:
WOS Id: 000423818400008
ID de PubMed: 29315334
imagen Green Submitted, Green Published, Green Accepted, gold

MÉTRICAS